title: Urinary albumin excretion in short children treated with recombinant human growth hormone.
abstract: The urinary levels of albumin, beta 2-microglobulin (BMG) and beta-D-N-acetyl glucosaminidase (NAG) were studied in 30 children with short stature due to partial or complete growth hormone (GH) deficiency under treatment. All 30 children had a normal urinalysis and no clinical evidence of renal disease. They were treated with recombinant GH in a dose of 0.5 IU/kg/week given subcutaneously. The mean albumin excretion rate (9.13 +/- 8.33 micrograms/min/1.73 m2) of these children was significantly higher than that (4.2 +/- 2.27 micrograms/min/1.73 m2) of 30 age-, sex- and pubertal status-matched normal children (p < 0.01). BMG and NAG excretion was normal in both groups. There was no correlation between the urinary albumin excretion rate and the duration of GH treatment. Among the GH-treated children, the urinary albumin excretion rate was correlated significantly with circulatory insulin-like growth factor I (IGF-I) (r = 0.65, p < 0.01). In 7 other children analyzed before and three months after start of GH treatment, the mean urinary albumin excretion rate increased significantly from 4.71 +/- 3.95 micrograms/min/1.73 m2 to 8.29 +/- 2.70 micrograms/min/1.73 m2 (p < 0.03). These results suggest the possibility of functional glomerular alterations during GH therapy.
authors.affiliation: Department of Pediatrics, Kurashiki Central Hospital, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Sasaki
authors.forename: N
authors.initials: N
authors.lastname: Takeda
authors.forename: I
authors.initials: I
authors.lastname: Kawamura
authors.forename: Y
authors.initials: Y
authors.lastname: Nishida
authors.forename: K
authors.initials: K
authors.lastname: Kikuchi
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
mesh_terms: D000118:Acetylglucosaminidase / Q000652:urine; D000293:Adolescent; D000419:Albuminuria / Q000652:urine*; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000188:drug therapy* / Q000652:urine; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D011863:Radioimmunoassay; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin / Q000652:urine
chemical_list: D011994:Recombinant Proteins; D001613:beta 2-Microglobulin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D000118:Acetylglucosaminidase